Endocrinology

A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.

The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

A new study suggests implementation of a low-cost clinical decision support tool reduces hypoglycemia risk in older adults with type 2 diabetes.

In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.

A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.

The FDA warns semaglutide (Ozempic) users of increased ileus risk and hypoglycemia with insulin secretagogues.

A 20-year analysis reveals over 25% of US adults have cardiac, renal, or metabolic conditions, with disparities in age and race.

Announced by Ionis Pharmaceuticals, topline results show olezarsen met the study's primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.

According to the analysis, high-performing primary care practices use similar strategies to manage change and quality improvement in care for people with diabetes.

A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.

Sarah Wheeler, PharmD, and John Bucheit, PharmD, provide perspective on contemporary trends in screening and management of nonalcoholic fatty liver disease in people with type 2 diabetes.

An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a breakdown of the latest news in diabetes management, including FDA clearance of a new insulin pump and a major acquisition within the diabetes world.

An analysis of data from more than 60,000 women details associations between specific chronotypes and risk of unhealthy lifestyle behaviors as well as risk of developing type 2 diabetes.

An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.

In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

A 1-year observational follow-up of a 3-month RCT provides insight into he benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?

In this episode, hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers.

Using data from the ASPREE trial, a new study from EASD 2023 suggests use of low-dose aspirin in older adults could reduce the risk of developing type 2 diabetes.

During this episode, hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes.

In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes.

On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.

Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.

An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.

Across 31 centers in England, hybrid closed-loop therapy was associated with improvements in HbA1c, sensor glucometrics, and diabetes-related distress in adults with T1D.

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.

Early rapid weight gain after diagnosis of T1D may play a role in the lack of remission and shorter duration of partial remission, potentially due to altered insulin sensitivity.